Skip to main content

Moderna and Merck will jointly develop a cancer vaccine for high-risk melanoma patients

Moderna's vaccine is being studied in combination with Merck's Keytruda to treat patients with high-risk melanoma, the deadliest form skin cancer.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.